MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
September 19 2007 - 6:15AM
PR Newswire (US)
FT. LAUDERDALE, Fla., Sept. 19 /PRNewswire-FirstCall/ -- MAKO
Surgical Corp. today announced that it has filed a registration
statement on Form S-1 with the U.S. Securities and Exchange
Commission relating to a proposed initial public offering of its
common stock. All of the offered shares will be sold by MAKO
Surgical Corp. The number of shares to be offered and the price
range of the offering have not yet been determined. The Company
intends to apply to have its common stock approved for quotation on
the NASDAQ Global Market under the symbol "MAKO." J.P. Morgan
Securities Inc. and Morgan Stanley & Co. Incorporated will act
as joint bookrunners for the offering and Cowen and Company, LLC
and Wachovia Capital Markets, LLC will act as co-lead managers. The
offering will be made only by means of a prospectus. Copies of the
preliminary prospectus for the offering, when available, may be
obtained from: J.P. Morgan Securities Inc., National Statement
Processing, Prospectus Library, 4 Chase Metrotech Center, CS Level,
Brooklyn, NY 11245 or by phone at (718) 242-8002; or Morgan Stanley
& Co. Incorporated's prospectus department at 180 Varick, New
York, NY 10014, by telephone at (866) 718-1649 or by emailing .
About MAKO Surgical Corp. MAKO Surgical Corp. is a medical device
company that markets its advanced robotic solution and implants for
minimally invasive orthopedic knee procedures. MAKO's Haptic
Guidance System(TM) includes an interactive haptic robotics
platform that utilizes tactile-guided robotics and patient-specific
visualization to prepare the knee joint for the insertion and
alignment of resurfacing implants through a keyhole incision. This
FDA-cleared surgeon- interactive haptic robotic system allows
surgeons to provide an innovative tissue-sparing bone resurfacing
therapy called MAKOplasty(TM) to a large, yet underserved
patient-specific population suffering from early to mid-stage
osteoarthritic knee disease. As of September 18, 2007, 80
MAKOplasty procedures have been performed since commercial
introduction in June 2006. MAKO has an intellectual property
portfolio of more than two hundred licensed or owned patent
applications relating to the areas of computer assisted surgery,
haptics, robotics, and implants. A registration statement relating
to these securities has been filed with the U.S. Securities and
Exchange Commission, but has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior
to the time the registration statement becomes effective. This news
release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities
in any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state. DATASOURCE: MAKO Surgical Corp.
CONTACT: Susan M. Verde of MAKO Surgical Corp., +1-954-927-2044,
x349,
Copyright